CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Hemin +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01206582
NCT01206582Phase 2Completed
CompareCT.gov

A Pilot Study of Hemin Therapy for Gastroparesis

Mayo Clinic·interventional·Posted Sep 22, 2010·Updated Feb 4, 2016

In Brief

A Phase 2 clinical trial evaluating Hemin and Albumin for Gastroparesis and Diabetes Mellitus. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study is designed to learn if hemin can increase the production of heme oxygenase 1 and improve gastric (stomach) emptying and symptoms in diabetic patients with slow gastric emptying (gastroparesis).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroparesis, Diabetes Mellitus
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), RECORDATI GROUP

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 22, 2010
Enrollment StartMay 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.8 years ago

Interventions

Heminbiological

10 iv infusions for 8 weeks

Albuminbiological

10 iv infusions for 8 weeks